High-Throughput Serology Assay Development

The contract requires the design, validation, and delivery of a high-throughput serology platform intended to match or surpass the performance of the current hemagglutination inhibition (HAI) assay used for influenza surveillance. The platform must be scalable and robust enough to support large-scale, rapid serological testing, ensuring accurate and consistent data collection for public health monitoring. Development must adhere to stringent performance benchmarks, with a focus on improving throughput, precision, and reproducibility across diverse influenza strains and sample types. This is a subcontract under the Department of Defense’s FA9000 AFGPO program, with performance centered at DWG. The North American Industry Classification System code 541711 indicates it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 15, 2026, and the work is expected to advance the DoD’s capability in infectious disease surveillance by replacing aging laboratory methods with a next-generation automated system. While no set-aside or point of contact details are provided, the project’s success is critical to maintaining national-level preparedness for seasonal and pandemic influenza threats.